Role of Clonal Hematopoiesis and NETs Formation in Unusual Venous Thrombosis (CLODETTE)

What this Trial Is About

Researchers are investigating venous thromboembolic diseases like deep venous thrombosis and pulmonary embolism, especially in patients with repeated or unusual site thrombosis where standard causes are not found. The study focuses on two factors recently linked to blood clotting: clonal hematopoiesis of indeterminate potential (CHIP), where blood cells have mutations, and the formation of neutrophil extracellular traps (NETs), which may contribute to clot formation. This research aims to better understand how these factors relate to venous thrombosis in patients under 50 years old with no identifiable risk factors. Participants will undergo additional blood sampling to check for CHIP using next-generation sequencing and to measure NETosis markers through plasma analysis. The study will compare these markers in patients with repeated venous thrombosis or thrombosis in unusual sites such as splanchnic or cerebral veins. The research will analyze the presence and relationship of CHIP and NETs to assess their role in thrombosis development. During the study, patients will have blood drawn at baseline for various tests including CHIP detection, NETosis marker levels, inflammation markers like C-reactive protein, and documentation of thrombosis sites and frequency. Researchers will use this data to evaluate the prevalence of CHIP and NETosis in the study group and their potential correlation. The study is planned to continue until March 2027, and all assessments are conducted at baseline to gather comprehensive information about the participants' condition and blood markers.

Clonal Hematopoiesis and NETs Formation in Venous Thrombosis (CLODETTE)